<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="../../web/xslt/drug-table.xslt"?><drug name = "lopinavir-ritonavir liq ORAL">
<dose><value>5</value>
<value>10</value>
<value>12</value>
<value>230/57.5</value>
<value>13</value>
<value>11</value>
<value>300/75</value>
</dose><route><value>PO</value>
</route><form><value>liq ORAL</value>
</form><drugname><value>lopinavir-ritonavir liq ORAL</value>
</drugname><strength><value>80 mg-20 mg/mL</value>
</strength><frequency><value>BID</value>
<value>DAILY</value>
</frequency><instruction></instruction><volume><value>160 mL</value>
</volume><units><value>mL</value>
<value>mg/kg</value>
<value>mg/m2</value>
</units><additionalnotes><value>Patients weighing from 7 to less than 15 kg, without concomitant efavirenz, nevirapine, nelfinavir or amprenavir.</value>
<value>Patients weighing from 15 kg to 40 kg, without concomitant efavirenz, nevirapine, nelfinavir or amprenavir.</value>
<value>Patients not receiving concomitant efavirenz, nevirapine, nelfinavir or amprenavir.</value>
<value>Patients weighing from 7 to less than 15 kg, with concomitant efavirenz, nevirapine, nelfinavir or amprenavir.</value>
<value>Patients weighing from 15 kg to 45 kg, with concomitant efavirenz, nevirapine, nelfinavir or amprenavir.</value>
<value>Patients receiving concomitant efavirenz, nevirapine, nelfinavir or amprenavir.</value>
</additionalnotes><population></population><indicationprn></indicationprn><backgroundinformation><value>Dosing based upon lopinavir component</value>
</backgroundinformation><prninformation></prninformation><ahsformularystatus><value>Formulary with Restrictions.</value>
</ahsformularystatus><ahfsname><value>Antivirals, Antiretrovirals</value>
</ahfsname><highalert></highalert><maximumprndose></maximumprndose><din><value>02243644</value>
</din><type><value>Medication/IV Therapy</value>
</type></drug>